What Obesity Drug Cost Models Show

What the review examined

A September 2026 systematic literature review in the British Journal of Clinical Pharmacology examined full economic evaluations of approved anti-obesity medicines in adults with overweight or obesity. The authors searched bibliographic databases and government websites. They assessed methodological quality with the BMJ checklist and reporting with CHEERS 2022. The review was registered on PROSPERO and followed PRISMA guidance.^[1]

The review included semaglutide and tirzepatide, alongside liraglutide and older anti-obesity medicines. Its purpose was to synthesize economic evidence for reimbursement and access discussions. It was not a clinical trial, a price list, an insurance decision, or a recommendation that an individual should start or change a medicine.

What cost-effectiveness means

Economic evaluations commonly compare an intervention's costs with health outcomes such as quality-adjusted life years, often summarized as an incremental cost-effectiveness ratio, or ICER. This is a modeling framework for comparing options under stated assumptions. It does not mean that a medicine is affordable to every patient, that it will be covered by every plan, or that it produces the same value in every healthcare system.

The distinction between cost-effectiveness and affordability is central to the source. A model can estimate favorable value relative to a threshold while a payer still faces a large total budget impact because many people may be eligible. Conversely, a lower-priced medicine can look economically competitive without necessarily being the preferred clinical option for a particular person.

What patterns the authors found

Twenty-six evaluations met the review's criteria. The included work came from high- or upper-middle-income countries and was predominantly conducted from payer perspectives. The authors report heterogeneous results that were sensitive to model assumptions, while also identifying recurring patterns across the studies.^[1]

For semaglutide, the review reports variable cost-effectiveness, although it consistently outperformed liraglutide in the included comparisons. For tirzepatide, the review describes greater modeled health gains and frequently favorable ICERs, while noting that it often exceeded willingness-to-pay thresholds in lower-threshold settings. These are synthesized model results, not a guarantee of value or access in a given country.^[1]

Why models can disagree

A cost model depends on inputs. Drug acquisition cost and treatment duration can change the result, as can assumptions about later healthcare costs. The review explicitly says its results were heterogeneous and sensitive to assumptions. Therefore, a conclusion from one setting should not be copied into another setting without checking the relevant price and decision threshold.^[1]

Long-term data are another limitation. The authors call for longer real-world evidence and clearer separation of cost-effectiveness from affordability. A model necessarily extends beyond the observed data by making assumptions. That does not make modeling useless, but it means the conclusion is conditional on its inputs rather than a permanent fact about a medicine.

What this says about newer medicines

The review notes that direct comparative economic evidence between newer agents remains limited. It also reports that phentermine/topiramate appeared economically competitive in part because of lower acquisition costs. That observation should not be reframed as a universal ranking of safety, effectiveness, or clinical suitability. Economic competitiveness is one dimension of a decision, not the entire decision.^[1]

The review's country limitation is practical, not merely technical. The included evaluations were conducted in high- or upper-middle-income countries, mostly from payer perspectives. A model designed around one health system's medicine price, service use, and willingness-to-pay threshold may have little relevance in another. Even within a country, negotiated prices and benefit design can differ. Readers should therefore ask which perspective was used before applying a headline figure to a plan, employer, clinic, or household budget.

Readers looking for background on medicines discussed in the review can consult our semaglutide and tirzepatide pages. The review discusses liraglutide as well, but these linked pages provide general reference material only and do not determine coverage, pricing, or individual treatment choices.

How to use this evidence responsibly

The strongest reading of this review is that anti-obesity medicine economics are context-dependent. The source supports discussion of uncertainty, country and payer perspective, and the value of transparent assumptions. It does not support a claim that semaglutide or tirzepatide is always cost-effective, that one modeled result applies worldwide, or that cost-effectiveness establishes clinical appropriateness for an individual.

Policymakers and payers may use economic evidence alongside clinical evidence, negotiated prices, budget impact, and equity considerations. Individuals face a different question: whether a particular treatment is appropriate and accessible in their own circumstances. Those questions require current local information and clinical discussion, not an abstracted model result. General regulatory context is available in our regulation section.

Medical disclaimer: this educational article is not medical advice and does not provide dosing, prescribing, or insurance-navigation instructions. Decisions about obesity treatment should be made with a qualified healthcare professional and, where relevant, a coverage provider. The review adds a useful economic lens, but it does not replace clinical judgment or a current local coverage determination.